Compare PNFP & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PNFP | JAZZ |
|---|---|---|
| Founded | 2000 | 2003 |
| Country | United States | Ireland |
| Employees | 3595 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.3B | 15.0B |
| IPO Year | N/A | 2007 |
| Metric | PNFP | JAZZ |
|---|---|---|
| Price | $100.30 | $229.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 14 |
| Target Price | $113.31 | ★ $217.57 |
| AVG Volume (30 Days) | ★ 1.3M | 872.7K |
| Earning Date | 04-22-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.05% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 4.43 |
| Revenue | N/A | ★ $1,618,693,000.00 |
| Revenue This Year | $160.52 | $6.22 |
| Revenue Next Year | $9.24 | $7.68 |
| P/E Ratio | ★ $12.24 | $51.09 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $81.08 | $105.00 |
| 52 Week High | $120.39 | $243.32 |
| Indicator | PNFP | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 62.54 | 52.02 |
| Support Level | $92.68 | $222.49 |
| Resistance Level | $100.91 | $242.66 |
| Average True Range (ATR) | 2.80 | 6.56 |
| MACD | 0.42 | -1.07 |
| Stochastic Oscillator | 99.73 | 47.72 |
Pinnacle Financial Partners Inc is a financial holding company. The company operates through its wholly-owned subsidiary, Pinnacle Bank. The bank provides a full range of lending products, including commercial, real estate, and consumer loans to individuals and small to medium-sized businesses. It operates as a community bank mainly in the urban markets of Nashville, Knoxville, Memphis, and Chattanooga, Tennessee, as well as surrounding counties. It relies heavily on mergers and acquisitions. A majority of its loan portfolio is in commercial loans, mainly real estate, as well as industrial loans. The bank generates a majority of its net revenue through net interest income.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.